Compare IDEXX Laboratories, Inc. (IDXX) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs UiPath Inc — how do they compare? IDEXX Laboratories, Inc. trades at $552.44 (market cap $44.48B), while UiPath Inc trades at $11.93 (market cap $6.30B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.1× UiPath Inc's market cap, and UiPath Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | PATH | |
|---|---|---|
Market Cap | $44.48B | $6.30B |
Sector | Health | Technology |
52-Week High | $766.68 | $19.29 |
52-Week Low | $520.87 | $9.38 |
Enterprise Value | $45.38B | $5.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
UiPath (PATH) trades at $12.26, up 0.91% today, with a bullish technical outlook and strong support at $12. The company shows improving fundamentals, with revenue growing to $1.43B in 2025 and a projected net profit of $327M in 2026. Recent news highlights AI partnerships and agentic automation growth, though Q1 2026 EPS missed expectations.
Outlook is cautiously optimistic with a consensus price target of $13.33, offering ~9% upside. Key opportunities include high gross margins and AI adoption, while risks involve execution on profitability and competitive pressures. Institutional sentiment is mixed with 25% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
